---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-280141"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:31:54.242054+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioAtla Q3 net loss $15.8M; FDA aligns on Phase 3 Oz-V design; partnership on track by year-end

## Summary
- Q3 2025 net loss $15.8M vs $10.6M in 2024 (which included $11M Context collaboration revenue); cash $8.3M at Sept 30.
- FDA alignment achieved on Phase 3 Oz-V trial for 2L+ OPSCC; dual primary endpoints (ORR and OS) with potential accelerated approval.
- Company in advanced stages to finalize a strategic transaction by year-end; Context milestone payment of $2M received.
- BA3182 (CAB-EpCAM x CD3 TCE) Phase 1 dose escalation ongoing; readout expected in first half 2026.
- R&D expenses decreased to $9.5M from $16.4M due to program prioritization and workforce reduction in March 2025.

## SEC filing metadata
- accession: 0001193125-25-280141
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312525280141/0001193125-25-280141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312525280141/bcab-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-280141
- JSON: https://secwatch.observer/filing/0001193125-25-280141.json
- Plain text: https://secwatch.observer/filing/0001193125-25-280141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.